solution by MARKET
Pharmaceutical Production Lines & Turnkey Factory Solutions for Saudi Arabia
From IV solution filling lines and injectable systems to OSD plants and cleanroom engineering — GMP-compliant manufacturing infrastructure built to support Vision 2030 pharmaceutical localization.
A Clear View of the Local Market Landscape
Saudi Arabia’s pharmaceutical market is projected to grow from USD 12.37 billion in 2025 to USD 18.12 billion by 2030, at a CAGR of 7.93%. Local manufactured medicines make up less than 30% of the total pharmaceutical market, with much of the spending continuing to flow overseas — making pharmaceutical localization a national priority under Vision 2030. The NDLP program aims to localize 40% of the value of the Saudi pharmaceutical industry, creating massive demand for new GMP-compliant production facilities, equipment, and turnkey factory infrastructure across the Kingdom.

Demand Trends Within the Country
-
Pharmaceutical Manufacturing Localization
Saudi Arabia intends to increase its share of domestic pharmaceutical manufacturing from 20% to 40%, driving urgent demand for new production lines and complete factory builds across injectable, OSD, and biologics segments. -
Injectable & IV Solution Production
New manufacturing facilities focused on producing complex medications including oncology and injectable drugs are being launched, reflecting the Kingdom’s push to localize sterile manufacturing capacity. -
Chronic Disease Drug Manufacturing
The growing burden of diabetes, cardiovascular diseases, respiratory disorders, cancer, and infectious diseases is increasing the demand for locally produced medications, particularly OSD and injectable formulations. -
Biologics & Vaccine Infrastructure
Biologic medicines represent the fastest-growing segment, and Vision 2030 initiatives have targeted the Kingdom’s historical lack of domestic biologics production capacity.
Local Experience, Reliable Execution
-
Proven Middle East delivery track record — 2,500+ production lines deployed in 60+ countries, with extensive project experience across the GCC and MENA region.
-
SFDA & international GMP alignment — All systems pre-engineered to meet EU GMP, US FDA cGMP, WHO GMP, and PIC/S GMP standards, fully aligned with SFDA’s recognition of PIC/S GMP guidelines and its GMP inspection requirements.
-
Full turnkey EPC capability — From consulting and process design through equipment manufacturing, cleanroom construction, utility installation, IQ/OQ/PQ validation, technology transfer, and operator training — one partner, one contract.
-
Customized for Saudi priorities — Solutions tailored for the Kingdom’s highest-demand therapeutic areas (diabetes, cardiovascular, oncology, respiratory) and configured for Vision 2030 localization requirements including NUPCO procurement alignment.
Selected Products for This Market
Meeting Local Standards with Reliable Delivery
Compliance & Certification
Logistics & Delivery
Success Snapshot
-
Pharmaceutical Manufacturer
Delivered an integrated injectable production facility including vial filling line, WFI system, Grade A/B cleanroom, and automated packaging. The facility passed SFDA GMP inspection on first audit and achieved annual fill-finish capacity of 25 million vials, enabling the client to supply NUPCO-contracted oncology and antibiotic products.
-
Healthcare Investment Group
Supplied a complete OSD turnkey plant including tablet and capsule lines, purified water system, cleanroom, and blister packaging for a greenfield factory in Dammam. The project was completed in 16 months and achieved SFDA GMP licensing, enabling production of 15 generic products targeting diabetes, cardiovascular, and respiratory therapies.
Trusted by Local Customers
-
“IVEN delivered our entire injectable facility as a single turnkey project — equipment, cleanroom, water system, and packaging. Their understanding of SFDA requirements and Vision 2030 localization standards accelerated our GMP approval significantly.”
Mr. F
CEO
-
“Their OSD factory solution gave us everything under one contract. The technology transfer was thorough, and our Saudi operators were production-ready within weeks. We’re now supplying NUPCO with 15 essential medicines.”
Dr. M
VP of Operations













